{"name":"Chipscreen Biosciences, Ltd.","slug":"chipscreen-biosciences-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Chiauranib","genericName":"Chiauranib","slug":"chiauranib","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"adriacin","genericName":"adriacin","slug":"adriacin","indication":"Acute lymphoid leukemia","status":"phase_1"}]}],"pipeline":[{"name":"Chiauranib","genericName":"Chiauranib","slug":"chiauranib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"adriacin","genericName":"adriacin","slug":"adriacin","phase":"phase_1","mechanism":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","indications":["Acute lymphoid leukemia","Acute myeloid leukemia, disease","Advanced ovarian cancer","Burkitt's lymphoma","Carcinoma of breast"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPeFp2ZGtZME52aUJYTmg1NzhKd3hDOEk4SGV2OC1DdU8zZHJMbGhCdi1rQTVWRnNNQzdXTkF0YTRBQzJfNVhNYTlZTDhMSjd5TnA5Mm9DcGh0T1RYaEJ0LUxFQ2MwaFNzdUl4bmVzMFE5bTNiVG5MOUxxSHBsOC1vam15d0hVZFFWazh0RVg4Vkc5aFJwV05jUWc3bWtGT0d0aG1wLTlqelRwT0VpSUhaM0FrbDVEM18z?oc=5","date":"2026-04-06","type":"pipeline","source":"Markets Mojo","summary":"Shenzhen Chipscreen Biosciences Hits Day High with 4.6% Surge - Markets Mojo","headline":"Shenzhen Chipscreen Biosciences Hits Day High with 4.6% Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNc0hMd1hZNjhZRTljMW1Qd0xDaTJKOWFGSmFYNGxyT3BGQ1hJakx6cjIxYjdjRGJqYW1uQlpTMEpUSmZydy1SQXpNMEJRYmx5bk5OTnNvZ1E5YVVhbmJHWktOVXVIQ2F2U0x6M0dkZlFpM3FxVklKcXp4emZKdlgwQmJZT2dKdlZjVWxsTndXVWpoR1htUzVWNjdQU0E3WTk0VlpGdjBGMGNxUlR4QURHM21hTkN4TXd5Rmc?oc=5","date":"2026-03-17","type":"pipeline","source":"Markets Mojo","summary":"Shenzhen Chipscreen Biosciences Hits Day High with 4.44% Surge - Markets Mojo","headline":"Shenzhen Chipscreen Biosciences Hits Day High with 4.44% Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNckNndDlCa2FmZ1J1ZUpHamhIcjI3NVBVVkVCV1hYNFBMb1lmVmE4NGJyNmlaQ2hiVGZFbjVuWGtrcVZGdVZEdW91NkJQZ1RjVm1WRS04TWFHOWdSOFo4WlBzYVhBQkVTVlRPM19lSVBwcmxIa1NVTXpRWDlsLTVJV3hTM2FaLXdjTTdmZVpSLXJEWFZvVHU2c0RPYmx4RXdCWnctN1FHU3hzaHNZVWM4MUt6aWM5YXRnYzk4b2dtekpwRGtxSXpXOWxtOGlHaTlCTG93U25sUGF5ZHhBUjBmTWRDczluSDJWc3pONXR1aWMtYWk2NlFoS21VNk4xQVAwN3l3M0VuN25tR3NBcjU2bmQzbGhRZkRvNUxJMTc4QQ?oc=5","date":"2025-12-29","type":"pipeline","source":"prnewswire.com","summary":"Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards - prnewswire.com","headline":"Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQVzdMMWJULWVjYzhsdExRZmRRWHFHTFB3U1RGd3JtQWVXSEt1bWdWbElFRE5BXzlYZ1VZYWxDYmJGaTR5Q2J3STVRV2piTHluNmVNN2N4MUVJWTMyWlFNa2tSeUgzeFVCR0pvb0FPTWJHMVBQaU1iandhalJ1UGJhT3Y5X3EzbU5VcHBXNGVzNVF5RnFUejZpNHp2d0FTcVlQeXBDRE5wS21xVkgxVmg1eTY0ODZIeUU1Y2NVM1hyZFNlLUxqUVBQcDBzY21tNDJwNGtQNWMtSGV5WVc1Tkl0Y1hUczNuQUIxMnVMTA?oc=5","date":"2024-10-07","type":"pipeline","source":"GlobeNewswire","summary":"Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight - GlobeNewswire","headline":"Innovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQTnFBZFpYM1JaaTF4UGtyZmlHQm1rSjVlSWgzOHNob1V6M1hzTGNha0hCMlBRZmdqLWxOZmI5MEJ5Z09HS1l0M1ktajZ1enNzYzBxYmtKMFlQajFBcTRuMVlBM3JFVFZ5My14Nm5vaXFpRWktTW5MSDlkZkRKM05mOExFX0JkVFhGUWZNejF3eXYtSi1Ga0Jr?oc=5","date":"2024-07-17","type":"pipeline","source":"BioWorld News","summary":"Sotio, Biocytogen link up in $325M ADC discovery pact - BioWorld News","headline":"Sotio, Biocytogen link up in $325M ADC discovery pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOcUE0ZjduT09iN3ZKUnFMQXEwSGplWlpUWk8wSWgyeHNjMno3cjNpRjc2S2MtSmxqdHo1LTdQQzN3MFBCWUkxd1VGWmlkUXlKUXBjb3I3RG40azR6WmIzZjl5ZTQ4QmZmYU1FeWlSRkNQbl92R3ZjRXpxbGxNMGZjZURIR2ZVaHZxS0M5MHdNMFZucWl6TU5qTXdKbzZoTFJFS1o3V0s3M3A1VGNnSW5ab3dBMkZOdWxobWV5bW1fdlAtSVhoR3JGQWpxcW13bk1YSGc?oc=5","date":"2024-03-19","type":"trial","source":"BioPharma APAC","summary":"Chipscreen Biosciences Announces Successful Phase II Trial of Chiglitazar for NASH Treatment - BioPharma APAC","headline":"Chipscreen Biosciences Announces Successful Phase II Trial of Chiglitazar for NASH Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQZFVNZjlUZ0xsNWUyempLMTAtQnE2NWI5RUEzMXNMU3pyRDRzMFlEOGxzT2pJcWxQNktLLTRxYlhFUjhEOXRrc2VmREpodUx5VEI5VzJjRWVfc0I2Y0JUUUVZYWJOMU5Lc2FwTmxwdk9HZk1KeEFnNlJTNk9YMnc1NjRTRWtlUHpDUW1WalZMcWREN2hDaUk4?oc=5","date":"2023-05-17","type":"pipeline","source":"openPR.com","summary":"Ovarian Cancer Pipeline Assessment (2023 Updates) | In-depth - openPR.com","headline":"Ovarian Cancer Pipeline Assessment (2023 Updates) | In-depth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNTmtpYURaVEhPYkNqc0FkczdWaHNyQXpkVXRSaVRUT0RDTm42bDQ1N1d3eDh6ZXd6czdkVGdPak5IbGxaekROMEduQnJ2LUdzMFJpbTNyVlRuVDBQMmxHbFZFTlBOS3JvbkgwMVYxSEJnenNnU0dvaF9yUDMtTmxjcXVMeWRxX1hMZ3hTcXdVdFpGM0tUYjFmdHIxbDh4OE5iTVlBQ3Q4V2JyY0g1cWpnZmdzV21yMktObTJNMmY3X2FBQ2R0aXBKbEtOOElkdS1iSnd3SGNRWHNlYzdVT3VBTkh4cklVU0dsaWF2dlhmUnZKNmRBLUplLVhpSm8tODJnNVdHVWlxQUR3U1ZIRVFxYVdPczVMSXhxOGc?oc=5","date":"2023-05-10","type":"pipeline","source":"prnewswire.com","summary":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain | DelveInsight - prnewswire.com","headline":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}